Company intelligence / Profile preview

Excellmab

Singapore, Singapore

Ownership: Private
Development stage: Other

Overview

Clinical trials for toripalimab (anti-PD-1 monoclonal antibody) are ongoing and the drug has marketing approvals in China for six oncology indications; regulatory submissions and approvals are progressing internationally and Excellmab is responsible for development and commercialization in 9 Southeast Asian countries.

Therapeutic areas: Oncology
Modalities: Monoclonal antibody
Industry: Biotech

Partnerships

Junshi BiosciencesRxilient BiotechChina Medical System Holdings Limited (indirectly, as Rxilient's parent)

Beyond the preview

Go deeper on Excellmab.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Excellmab.

Explore the full profile